GSK raised its full-year guidance after second quarter core earnings rose 13%, helped by higher sales in oncology, HIV and its general medicines portfolio.
Related Posts
NASA Says Starliner Astronauts Could Return With SpaceX—Next Year
Officials confirmed at a briefing that NASA is considering using SpaceX for the return trip. Boeing says its craft is safe for crew.
Novo Nordisk’s Wegovy Weight-Loss Drug Gets Approval in China
Blockbuster obesity drug Wegovy has been approved in China, opening the door for maker Novo Nordisk to begin selling it in the world’s second-largest economy, […]
Why Your Starbucks Frappuccino Is Now Half-Price
The coffee chain, long known for premium brews, is pumping out more deals to woo price-sensitive customers.